JP2024522201A5 - - Google Patents

Info

Publication number
JP2024522201A5
JP2024522201A5 JP2023576071A JP2023576071A JP2024522201A5 JP 2024522201 A5 JP2024522201 A5 JP 2024522201A5 JP 2023576071 A JP2023576071 A JP 2023576071A JP 2023576071 A JP2023576071 A JP 2023576071A JP 2024522201 A5 JP2024522201 A5 JP 2024522201A5
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
haloalkyl
membered
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023576071A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522201A (ja
Filing date
Publication date
Priority claimed from GBGB2108249.0A external-priority patent/GB202108249D0/en
Application filed filed Critical
Publication of JP2024522201A publication Critical patent/JP2024522201A/ja
Publication of JP2024522201A5 publication Critical patent/JP2024522201A5/ja
Pending legal-status Critical Current

Links

JP2023576071A 2021-06-09 2022-06-09 置換された1,2-ジアミノヘテロサイクリック化合物誘導体の製造およびその薬剤としての用途 Pending JP2024522201A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2108249.0 2021-06-09
GBGB2108249.0A GB202108249D0 (en) 2021-06-09 2021-06-09 Compounds
PCT/KR2022/008105 WO2022260441A1 (en) 2021-06-09 2022-06-09 Preparation of substituted 1,2-diaminoheterocyclic compound derivatives and their use as pharmaceutical agents

Publications (2)

Publication Number Publication Date
JP2024522201A JP2024522201A (ja) 2024-06-11
JP2024522201A5 true JP2024522201A5 (cg-RX-API-DMAC10.html) 2026-04-28

Family

ID=76838874

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023576071A Pending JP2024522201A (ja) 2021-06-09 2022-06-09 置換された1,2-ジアミノヘテロサイクリック化合物誘導体の製造およびその薬剤としての用途

Country Status (10)

Country Link
US (1) US12698278B2 (cg-RX-API-DMAC10.html)
EP (1) EP4352049A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024522201A (cg-RX-API-DMAC10.html)
KR (1) KR20240006692A (cg-RX-API-DMAC10.html)
CN (1) CN117529476A (cg-RX-API-DMAC10.html)
AU (1) AU2022291332A1 (cg-RX-API-DMAC10.html)
CA (1) CA3216629A1 (cg-RX-API-DMAC10.html)
GB (1) GB202108249D0 (cg-RX-API-DMAC10.html)
MX (1) MX2023014784A (cg-RX-API-DMAC10.html)
WO (1) WO2022260441A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023397123A1 (en) * 2022-12-12 2025-02-13 Avelos Therapeutics Inc. Substituted heterocyclic compound derivatives and their pharmaceutical use
EP4637751A2 (en) * 2022-12-23 2025-10-29 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Foxm1 inhibitors and their use in treating cancers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
AR074199A1 (es) 2008-11-20 2010-12-29 Glaxosmithkline Llc Compuesto de 6-(4-pirimidinil)-1h-indazol, composiciones farmaceuticas que lo comprenden y su uso para preparar un medicamento util para el tratamiento o disminucion de la gravedad del cancer.
US9096584B2 (en) * 2010-05-12 2015-08-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9481670B2 (en) 2011-01-25 2016-11-01 Sphaera Pharma Pte. Ltd. Triazine compounds
PE20151412A1 (es) 2012-11-27 2015-10-10 Thomas Helledays Stiftelse For Medicinsk Forskning Derivados de pirimidin-2,4-diamina para el tratamiento de cancer
CN106794181A (zh) 2014-06-04 2017-05-31 托马斯·黑勒戴药物研究基金会 用于治疗炎性和自身免疫性病况的mth1抑制剂
JP7503054B2 (ja) * 2018-10-16 2024-06-19 ダナ-ファーバー キャンサー インスティテュート,インコーポレイテッド Lrrk2の野生型および変異型のアザインドール阻害剤

Similar Documents

Publication Publication Date Title
JP7326622B2 (ja) Erk阻害剤としてのスピロ系化合物およびその使用
JP5596680B2 (ja) 経口抗がん製剤
JP2021088610A5 (cg-RX-API-DMAC10.html)
EP3490565A1 (en) Chemokine receptor modulators and uses thereof
JP2010509375A5 (cg-RX-API-DMAC10.html)
JP2021534108A5 (cg-RX-API-DMAC10.html)
RU2007101653A (ru) Производные 1-азабицикло[3.3.1]нонанов
US10947225B2 (en) Phosphotidylinositol 3-kinase inhibitors
CN102584830A (zh) 二氢化茚酰胺化合物、其药物组合物及其用途
JP2023535815A5 (cg-RX-API-DMAC10.html)
JP2017524003A (ja) 薬物耐性癌の治療で用いるための脂肪酸シンターゼ阻害剤
CA2906196A1 (en) Enantiomerically enriched s-oxprenolol compositions for treating cancer
TWI719138B (zh) 四氫異喹啉衍生物
WO2024061097A1 (zh) 一种新颖的氨基甲酸酯类化合物及其用途
WO2016203468A1 (en) Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof
JP2002503674A5 (cg-RX-API-DMAC10.html)
CN116621857A (zh) 一种新颖的氨基甲酸酯类化合物及其用途
CN115677507B (zh) 氟比洛芬衍生物及其在药物中的应用
JP7245397B2 (ja) 複素環化合物
KR920016418A (ko) Nmda 길항제
JP7663605B2 (ja) ピリミジン系三環式化合物及びその使用
JP2024517789A5 (cg-RX-API-DMAC10.html)
JP2997894B2 (ja) 循環器系疾患の予防及び治療剤
KR20230049673A (ko) 피리미딘 카르복스아미드 화합물 및 이의 용도
JP6545254B2 (ja) リン含有フェナントロリン誘導体及びその調製方法と応用